Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients

摘要: Background/aims Dosage of serum AFP (alpha-fetoprotein) is widely used for HCC screening in patients with chronic liver disease. Virus-related disease the main cause cirrhosis and Western Far Eastern countries, but relationship between viral etiology levels still unclear. The aim this study was to verify, post-viral disease, usefulness dosage detection HCC, influence on HCC. Methodology population included 350 post that underwent biopsy, determination ultrasound evaluation. Seven had normal histology, 197 hepatitis, 72 cirrhosis, 74 ROC (receiver operating characteristic) analysis assess best diagnostic threshold value detection. Logistic regression performed individuate independent predictors diagnosis. Results No difference observed HCV- HBV-positive patients, neither whole nor only. area under curve 0.801 (95% CI: 0.721-0.867). individuated a accurate diagnosis 50 ng/mL. detected specificity > or = 95% only 100 sensitivity however poor (25%). Male sex, age 60, were Conclusions Serum are not influenced by virus B C hepatitis pattern. should be non-cirrhotic patients. regarded more "aggressive" program compared females.